Outcomes Associated with Lung Transplants Using Organ Care System (OCS) Lung in the United States
Recommended Citation
Loor G, Fernandez R, Patel K, Belli E, Lee A, Smith M, Salerno C, Song T, Siddique A, Langer N, Kukreja J, Nemeh H, Hartwig M, Daneshm M, Chan J, Schwartz G, Toyoda Y, Durham L, Ardehali A, Bush E, Suarez E, Hertz M, Garcha P. Outcomes Associated with Lung Transplants Using Organ Care System (OCS) Lung in the United States. J Heart Lung Transplant 2025; 44(4):S190-S191.
Document Type
Conference Proceeding
Publication Date
4-1-2025
Publication Title
J Heart Lung Transplant
Keywords
adult, cohort analysis, conference abstract, controlled study, cross clamp time, extracorporeal oxygenation, female, graft recipient, human, major clinical study, male, middle aged, oral drug administration, organ perfusion, secondary analysis, smoking, thoracic viscera, United States
Abstract
Purpose: The Thoracic Organ Perfusion (TOP) registry captures prospective real-world data on OCS lung use in the US. The current study reports perioperative characteristics and survival outcomes associated with transplants using OCS lung. Methods: All patients in this study were consented for participation in the TOP registry. Our primary outcome of interest was one-year survival. In a secondary analysis, we compared outcomes associated with a center-specific OCS procurement model (direct acquisition group), and a third-party OCS procurement model [National Organ Care System Program (NOP) group]. Results: 467 lungs were instrumented on OCS and only 9 were turned down after OCS preservation yielding a donor utilization rate of 98.1% (458/467). A total of 458 OCS patients were included in the current analysis. Of all donors in this cohort, 20% were older than 55 years of age, 24% were from donation after circulatory death (DCD), 8% had a PaO2:FiO2 ratio <300mmHg prior to retrieval, and 9% had a significant smoking history (>20 pack year with recent smoking within 6 months). Recipients’ mean age was 57.7 years old. Of all recipients, 11% were on ECMO prior to transplant, 35% had a lung allocation score >50, and 6% had a history of prior solid organ transplant. Average total cross clamp time was 619 min. 1-, 6- and 12-month survival was 97, 91, and 86%, respectively. There was no difference in survival between direct acquisition and NOP groups (p=0.28). Conclusion: The current analysis of transplant recipients in the TOP registry suggests that OCS lung was a safe preservation method for expanding the donor pool and extending cross-clamp times. NOP offers a safe alternative to facilitate procurement protocols and logistics. [Formula presented]
Volume
44
Issue
4
First Page
S190
Last Page
S191
